New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
09:05 EDTTHC, SALE, MSI, BLMN, CAR, FIVN, HIMX, AKRX, GTAT, ODP, CVS, GCI, COH, TGTOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Office Depot (ODP), up 6.9%... Coach (COH), up 4.3%... Akorn (AKRX), up 4.9%... Avis Budget (CAR), up 4.7%... GT Advanced (GTAT), up 3.7%... Tenet Healthcare (THC), up 1.9%... CVS Caremark (CVS), up 1.1%. HIGHER: Gannett (GCI), up 5.6% after acquiring remaining 73% interest in Classified Ventures for $1.8B, announcing plans to spin-off publishing business to shareholders... Himax (HIMX), up 4% after shares upgraded to Buy from Neutral at BofA Merrill Lynch. DOWN AFTER EARNINGS: Motorola Solutions (MSI), down 3.6%... Bloomin' Brands (BLMN), down 10.4%. LOWER: Target (TGT), down 4.6% after lowering its Q2 adjusted earnings per share view, updating on impact of data breach... RetailMeNot (SALE), down 20%, downgraded at RBC Capital following the company's Q2 report... Five9 (FIVN), down 22%, downgraded at Pacific Crest following lower than expected quarterly results.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
November 18, 2015
08:05 EDTTGTTarget reports Q3 SSS up 1.9%
Subscribe for More Information
08:04 EDTTGTTarget says returned $1.3B to shareholders in Q3
08:04 EDTTGTTarget narrows FY15 adjusted EPS view to $4.65-$4.75 from $4.60-$4.75
Subscribe for More Information
08:03 EDTTGTTarget sees Q4 adjusted EPS $1.48-$1.58, consensus $1.54
08:02 EDTTGTTarget narrows FY15 adjusted EPS view to $4.65-$4.75 from $4.60-$4.75
Subscribe for More Information
08:00 EDTTGTTarget reports Q3 adjusted EPS 86c, consensus 86c
Subscribe for More Information
07:57 EDTCARBarclays to hold a conference
Subscribe for More Information
07:46 EDTSALEJefferies hosts a summit
Subscribe for More Information
November 17, 2015
16:32 EDTMSIMotorola Solutions raises quarterly dividend 20% to 41c per share
Subscribe for More Information
15:17 EDTTGTTarget November 73 straddle priced for 6% movement into Q3
Subscribe for More Information
15:13 EDTTGTNotable companies reporting before tomorrow's open
Subscribe for More Information
12:53 EDTTGTEarnings Watch: Analysts bullish on Target's Q3 comps ahead of earnings report
Target (TGT) is scheduled to report third quarter results before the market open on Wednesday, November 18, with a conference call scheduled for 10:30 am ET. Target offers merchandise at discounted prices through its retail stores and online business. EXPECTATIONS: Analysts are looking for earnings per share of 86c on revenue of $17.57B, according to First Call. The consensus range for EPS is 81c-89c on revenue of $17.42B-$17.76B. In its last earnings report, Target forecast Q3 adjusted EPS 79c-89c Q3 comparable sales up 1%-2%. LAST QUARTER: Target reported second quarter adjusted EPS of $1.22, beating analysts' estimates for $1.11, on revenue of $17.43B, generally in line with analysts' $17.4B consensus. The company said comparable sales increased 2.4% in Q2. Looking ahead, Target raised its fiscal year 2015 adjusted EPS view to $4.60-$4.75 from $4.50-$4.65 against estimates at that time for $4.62. On its earnings conference call, Target said it felt "great" about its fourth quarter plans and said it will be "very promotional" in that quarter. NEWS: On August 25, Target said it expects to record a pretax gain of approximately $550M after closing the transaction with CVS Pharmacy (CVS) to sell its pharmacy and clinic businesses for cash consideration of approximately $1.9B. Target also entered into a development agreement with CVS, through which it may jointly develop small-format stores, Target said. The transaction is expected to be accretive to EPS after closing. On September 10, Cherokee (CHKE) announced that Target elected not to renew the license of the Cherokee brand in the U.S., which will expire at the end of its current term on January 31, 2017. Target said on September 30 that it will update its Price Match Policy by expanding digitally and extending its timeframe to 14 days compared to 7 days. The retailer later announced plans to bring back free shipping and returns through the holiday season. STREET RESEARCH: Ahead of the company's earnings report, Piper Jaffray analyst Sean Naughton acknowledged that while sentiment is challenging on Target's stock amid the weakness being reported by a number of retailers this week, he believes Target's Q3 SSS are within the company's guidance of up 1%-2%. The analyst believes Target's fundamentals may be holding up better than some expected. He has an Overweight rating and $88 price target on the stock. Stifel also believes Target will report an above Street comp of 2% versus consensus of 1.7% and inline earnings of 86c. Analyst David A. Schick checks indicate strong merchandising and customer response to key holidays and said PCE trends suggest there is still room for comp upside. Last week, Citi analyst Kate McShane said that in a head-to-head comparison between Costco Wholesale (COST), Target and Wal-Mart Stores (WMT), three of the biggest broadlines retailers in the world, Target is the "surprising" winner. McShane said that Target "wins" on potential for EPS growth, operating margin and valuation. PRICE ACTION: Target shares are down over 7% over the past three months. In early afternoon trading ahead of Wednesday's earnings report, shares are up about 1.7% to $73.54.
10:17 EDTCVSHouse Judiciary Committee to hold a hearing
The Subcommittee on Regulatory Reform, Commercial and Antitrust Law holds a hearing entitled, "The State of Competition in the Pharmacy Benefit Manager and Pharmacy Marketplaces" with Vice President Bricker of Express Scripts and Senior Vice President Pons of CVS Health on November 17 at 3 pm. Webcast Link
09:02 EDTTGTAnalyst pans competing products, says buy Fitbit
Shares of previous high-flier Fitbit (FIT) have dropped about 30% in the last two weeks following the company's third quarter earnings report, but an analyst at Bank of America upgraded his view of the fitness tracker maker this morning, saying that now is the time to buy ahead of fourth quarter results that may be boosted by the "underwhelming" new products being launched by its competitors. UNDERWHELMING COMPETITION: Fitbit's sales guidance for this holiday quarter looks conservative, contends Bank of America analyst Nat Schindler, who notes that the company only had the launch of one new product last December but will have the Charge, Charge HR and Surge to drive sales this season. Schindler also notes that the company's international advertising has expanded into more countries ahead of the holidays this year. Key, however, may be the "underwhelming" lineup of new or updated fitness trackers launched by competitors, such as the Microsoft's (MSFT) Band 2, Jawbone's UP4 and Sony's (SNE) Smartband 2, many of which have only minor improvements and no "must have" features to pull consumers away from Fitbit, Schindler told investors in his research note. PLATFORM PICKING UP STEAM: The analyst also pointed out that Fitbit now has more than 20 companies signed onto its health and wellness platform, including big names like Target (TGT) and Barclays (BCS), which he believes should help drive revenue beats in the upcoming fiscal year due to increased device sales. Also, the additional dashboard data should help Fitbit maintain long-term user engagement, said Schindler. APPLE WATCH: Apple's (AAPL) Apple Watch is largely viewed as the biggest potential competitive threat to Fitbit's offerings, but on the fitness tracker maker's last earnings call CEO James Park said Fitbit's products differ from those of its competitors in several key aspects, including pricing, cross-platform compatibility, brand awareness and product line breadth. Other wearables makers include Garmin (GRMN) and Samsung. PRICE ACTION: Since the day after Fitbit's last earnings report after the market close on November 2, its shares have fallen about 29.5% to close yesterday at $28.80. In pre-market trading this morning, Fitbit shares rose 2% to $29.40.
November 16, 2015
12:32 EDTFIVNFive9 management to meet with Needham
Meeting to be held in the Mid-Atlantic area on November 19 hosted by Needham.
10:01 EDTCARAvis Budget acquires Avis licensee in Poland
Subscribe for More Information
09:06 EDTCVSDiplomat seen as compelling amid specialty pharmacy fallout
Shares of specialty pharmacy operator Diplomat Pharmacy (DPLO) and pharmacy benefit manager Express Scripts (ESRX) have each been knocked down by the negative news surrounding the sector amid the troubles faced by Valeant (VRX) and others, but an analyst at Leerink contends in a note to investors that the pullbacks in both stocks provide buying opportunities. BACKGROUND: Drugmaker Valeant and its prior specialty pharmacy partner, Philidor Rx Services, have been at the center of the firestorm engulfing the sector. Following claims that Philidor urged its employees to modify prescriptions to ensure more orders of Valeant-branded drugs rather than generics, as well as other allegations of wrongdoing, Express Scripts (ESRX) and peer CVS Health (CVS) terminated Philidor from their networks. The day after those termination announcements, Valeant said that it was severing all ties with Philidor and that the pharmacy planned to shut down operations as soon as possible, consistent with applicable laws. Valeant has subsequently said that Philidor has committed to cease operations by January 30, 2016, at the latest. More recently, Express Scripts, the nation's largest pharmacy benefit manager, announced that it stopped doing business with Linden Care, accusing it of being a "captive" pharmacy that dispenses mostly products made by Horizon Pharma (HZNP). In turn, Horizon called the idea that Linden Care is a captive pharmacy "entirely false," stating that "at best Express Scripts is being reckless in its allegations and at worse it is intentionally attempting to mislead investors." Express Scripts' move also impacted shares of Insys Therapeutics (INSY), which reportedly also used Linden Care to fulfill prescription for its drugs. DIPLOMAT LIKELY TO STAY IN-NETWORK: Leerink analyst David Larsen acknowledged that recent events indicate that Express Scripts appears to be evaluating certain retail pharmacies and their relationships with manufacturers, but he believes Diplomat's mix of drugs for diseases like multiple sclerosis, HIV, hepatitis C and cancer differentiate it as a "true" specialty pharmacy. Larsen does not think Diplomat is at risk of being excluded from the pharmacy networks of Express Scripts, CVS or UnitedHealth's (UNH) Optum, he tells investors. Larsen expects limited distribution agreements to stay an important channel strategy for drugmakers and believes these agreements are appropriate for high cost specialty drugs that require special handling and additional services to manage patient adherence. The analyst, who thinks Diplomat remains well positioned to deliver annual growth of over 30% in the next several years, keeps an Outperform rating on its shares. EXPRESS BUYING OPPORTUNITY: Larsen also thinks concerns around manufacturer and pharmacy relationships have put unwarranted pressure on shares of Express Scripts. He does not expect Express Scripts to disclose new lawsuits around rebate dollars owed over other manufacturer disputes and keeps an Outperform rating on the stock, which he views as having an "attractive" valuation. WHAT'S NOTABLE: Larsen also thinks that the specialty channel remains an opportunity for Walgreens Boots Alliance (WBA) and believes its proposed acquisition of Rite Aid (RAD) can strengthen its specialty offering. The analyst keeps an Outperform rating on Walgreens shares as well. PRICE ACTION: Over the last three months, Diplomat Pharmacy shares have declined 28%, Express Scripts has fallen 6% and Walgreens has dropped 14%.
07:18 EDTCARDeutsche Bank to hold a conference
Subscribe for More Information
06:18 EDTCVSDiplomat Pharmacy selloff brings 'compelling' entry point, says Leerink
Subscribe for More Information
05:30 EDTODPStocks with implied volatility above IV index mean; ODP CRM
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use